Neuphoria Therapeutics Inc (NEUP) — Cash Flow Reinvestment Rate

Latest as of June 2025: 0.00x

Neuphoria Therapeutics Inc (NEUP) has a Cash Flow Reinvestment Rate of 0.00x as of June 2025, reinvesting $3.00 (capex $3.00 ) from operating cash flow of $73.57 Million. See free cash flow generation of Neuphoria Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.00x
(Capex + Investments) / Operating CF

Total Reinvested

$3.00
Capex + Investments

Operating Cash Flow

$73.57 Million
USD

Capital Expenditures

$3.00
USD

Neuphoria Therapeutics Inc Cash Flow Reinvestment Rate (2015–2025)

Historical reinvestment intensity for Neuphoria Therapeutics Inc across 2 annual periods. For the full cash flow conversion analysis, see NEUP cash generation efficiency.

Annual Cash Flow Reinvestment Rate for Neuphoria Therapeutics Inc (2015–2025)

Year-by-year capital reinvestment analysis for Neuphoria Therapeutics Inc. See NEUP free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 0.00x $0.00 $77.23 Million $0.00 ▼ -100.0%
2015 0.17x $846.26K $4.94 Million $846.26K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow